Scholarlink

<p>Rituximab is a monoclonal antibody used in the treatment of B-cell malignancies. Infusion reactions are common during the first exposure but decrease with subsequent infusions. We here present our experience with a protocol for a 30-minute intravenous infusion of rituximab (SpeedR) to patients who have previously tolerated a 90-minute rituximab infusion. All patients were premedicated with 10&#xa0;mg cetirizine and 1&#xa0;g paracetamol (steroids were only given when part of a concomitant chemotherapy regimen). In this cohort 268 patients received a total of 940 intravenous 30-minute infusions with only nine patients having adverse reactions (all grade 1–2) which required little or no treatment. Out of the nine patients with reactions, seven were planned for more rituximab treatment and all of them could later continue with 30-minute rituximab infusions. We conclude that 30-minute rituximab infusions are a safe and efficient way to optimize workflow in the outpatient clinic and to give cost-effective treatment to lymphoma patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A 30-minute intravenous infusion of rituximab is safe and cost-effective (SpeedR)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月31日

查看全文
  • Björn Engelbrekt Wahlin,
  • Maria Ljungqvist,
  • Ola Falk,
  • Therese Rådman,
  • Sandra Lindé,
  • Kristina Sonnevi

摘要

Rituximab is a monoclonal antibody used in the treatment of B-cell malignancies. Infusion reactions are common during the first exposure but decrease with subsequent infusions. We here present our experience with a protocol for a 30-minute intravenous infusion of rituximab (SpeedR) to patients who have previously tolerated a 90-minute rituximab infusion. All patients were premedicated with 10 mg cetirizine and 1 g paracetamol (steroids were only given when part of a concomitant chemotherapy regimen). In this cohort 268 patients received a total of 940 intravenous 30-minute infusions with only nine patients having adverse reactions (all grade 1–2) which required little or no treatment. Out of the nine patients with reactions, seven were planned for more rituximab treatment and all of them could later continue with 30-minute rituximab infusions. We conclude that 30-minute rituximab infusions are a safe and efficient way to optimize workflow in the outpatient clinic and to give cost-effective treatment to lymphoma patients.